Mitomics Announces U.S. Sales and Marketing Agreement with LabCorp
Urologists Able to Order Prostate Core Mitomic Test((TM)) through LabCorp’s DIANON Systems Laboratory
THUNDER BAY, ON, Oct. 10, 2012 /PRNewswire/ – Mitomics, a world leader in the
research and development of mitochondrial genome-based products, today
announced an agreement with Laboratory Corporation of America(® )Holdings (LabCorp(®)) (NYSE: LH), a leading provider of medical laboratory tests and
services. Under the agreement, urologists will be able to order
Mitomics’ flagship laboratory test, the Prostate Core Mitomic Test((TM)) (PCMT), through DIANON Systems, Inc., a specialized laboratory subsidiary of LabCorp focusing on
anatomic pathology, including uropathology. The PCMT was developed by
Mitomics and will be performed at Mitomics CLIA laboratory in Aurora,
“We are pleased to partner with LabCorp and DIANON to offer convenient
ordering of and information about PCMT to their urology customers
throughout the U.S.,” said Robert Poulter, president and chief
executive officer of Mitomics. “This agreement supports our commercial
strategy to provide broad access to PCMT and further validates the
strong demand from physicians to improve the diagnosis of prostate
cancer for patients.”
About the Prostate Core Mitomic Test((TM)) (PCMT)
PCMT is a highly advanced, patented test based on the science of
mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy
tissue, PCMT can determine the presence of malignant cells via a
cancerization field effect by detecting underlying molecular
alterations in normal-appearing tissue. This is all performed quickly
and easily with a simple lab test. For more information or to order
PCMT, please visit the PCMT web page.
Mitomics is the world leader in the research and development of
mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative
approach to the detection of cancer and other disease states.
Leveraging its unparalleled insights into the role of mitochondria in
cancer, the company is developing an extensive and proprietary
portfolio of molecular tests that address significant unmet needs in
oncology and gynecology, including those for the early detection of
prostate and breast cancer, as well as a test for endometriosis.
Mitomics currently markets the Prostate Core Mitomic Test((TM)), a highly accurate laboratory developed test for detecting the absence
or presence of cancerous cells using existing prostate biopsy tissue,
and plans to launch several additional breakthrough molecular tests
based on its Mitomic Technology((TM)) in the coming years. The company is headquartered in Thunder Bay,
Ontario, Canada and operates a CLIA compliant clinical laboratory in
Aurora, Colorado. For more information, please visit www.mitomicsinc.com.
SOURCE Mitomics Inc.